A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503571-19-00

Acronym

D9180C00003

Enrollment

479

Registered

2024-02-28

Start date

2022-01-20

Completion date

Unknown

Last updated

2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.

Interventions

DRUGTozorakimab-placebo

DRUGTozorakimab

DRUGSALBUTAMOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.	—

Countries

Belgium, Bulgaria, Czechia, Denmark, Finland, Hungary, Netherlands, Norway, Portugal, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026